“When scaling up a process based on adherent cells, a biopharmaceutical manufacturer has two options. Either stay in 2D, resulting in the use of heavy and difficult-to-handle multi-tray stacks with a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results